Recommendation of the President – Omjjara (momelotinib)

On 25 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 50/2025 on the appraisal of drug Omjjara (momelotinib) under drug program B.81. “Treatment of patients with Ph (-) myeloproliferative neoplasms (ICD-10: D45, D47.1)”

Publication in Public Information Bulletin (BIP) >>